# Quest for Growth

> Quest for Growth is a VC fund in Leuven backing Biotechnology, Hardware and Software. See 24 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Leuven, Belgium
- Total investments: 24
- Last investment: Jul 2024
- Lead investor: 4%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/quest-for-growth-qgplf-/about/
- Website: http://www.questforgrowth.com

Quest for Growth (QGPLF) is an Internet company located in 19 Lei, Leuven, Flanders, Belgium.

## Round sizes

| Stage | Round size |
| --- | --- |
| Series B | $510k–$65M |
| Series C | $8.1M–$21M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 7 | 29% |
| Hardware | 5 | 21% |
| Software | 5 | 21% |
| Medical | 4 | 17% |
| Health Care | 4 | 17% |

45 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 8 | 33% |
| Series B | 5 | 21% |
| Series C | 3 | 13% |
| Series D | 3 | 13% |
| Series A | 2 | 8% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Belgium | 8 | 33% |
| France | 4 | 17% |
| The Netherlands | 4 | 17% |
| Germany | 2 | 8% |
| United States | 2 | 8% |

8 countries tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Confo Therapeutics | Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO body-stabilized active state conformations ofthese receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention. | $65.2M | Series B | Jul 26, 2024 |  |
| Finquest | Finquest is the premier deal origination provider delivering personalized connections to its clients who seek M&A and direct investment opportunities in Europe, North America, and APAC.With a unique database, machine learning and a team of experts, Finquest provides targeted, curated and actionable connections, whilst maintaining completeconfidentiality throughout the process. With Finquest, clients can broaden their market access, creating a more efficient deal-making environment.Finquest is headquartered in Singapore and has offices in New York, London, Paris, Frankfurt, Luxembourg, Bangalore, and Hong Kong. | $5.5M | Seed | Jul 04, 2022 |  |
| Qpinch | Qpinch’re committed to bringing their innovative chemical heat transformer to your plant and to helping your business save on energy bills while reducing your environmental footprint. | $16.6M | Series B | Sep 09, 2021 |  |
| EclecticIQ | EclecticIQ is a global threat intelligence, hunting and response technology provider. Its clients are some of the most targeted organizations, globally. To build tomorrow’s defenses today, they have to understand the threats against them – and align their efforts and investments to mitigate their risks. EclecticIQ helps governments, largeenterprises and service providers manage threat intelligence, create situational awareness and adopt an intelligence-led cybersecurity approach. EclecticIQ extended its focus towards hunting and response with the acquisition of Polylogyx’s endpoint technology in 2020. Founded in 2014, EclecticIQ operates globally with offices across Europe, North America, and via value-add partners. More info: www.eclecticiq.com | $21.2M | Series C | Nov 30, 2020 |  |
| Sensolus | Sensolus provides care-free tracking of your valuable non-powered assets directly from the cloud.Sensolus offers turnkey solutions for wireless, low-power context-aware sensing. Sensolus developed a personal product line of low-power tracker systems called STICKNTRACK.Sensolus is built upon many years of expertise in low-power networks,wireless sensor design, cloud-based sensor management, analytics, and applications. | $4.1M | Venture - Series Unknown | Oct 06, 2020 |  |
| Miracor Medical | Miracor Medical operates as a medical device company. It develops and commercializes a pressure-controlled intermittent coronary sinus occlusion (PiCSO) impulse system for cardiac surgeons to facilitate the PiCSO treatment for myocardial infarction/heart attack patients undergoing coronary artery bypass grafting surgery. Miracor Medicaloffers a therapy for improving micro-vascular perfusion functions through the coronary sinus. Werner Mohl founded it in 2008, with its headquarters in Awans in Belgium. | $28.4M | Series E | Sep 02, 2020 |  |
| Miracor Medical | Miracor Medical operates as a medical device company. It develops and commercializes a pressure-controlled intermittent coronary sinus occlusion (PiCSO) impulse system for cardiac surgeons to facilitate the PiCSO treatment for myocardial infarction/heart attack patients undergoing coronary artery bypass grafting surgery. Miracor Medicaloffers a therapy for improving micro-vascular perfusion functions through the coronary sinus. Werner Mohl founded it in 2008, with its headquarters in Awans in Belgium. | $5.5M | Series D | Sep 04, 2018 |  |
| HalioDx | HalioDx designs and develops diagnostic tests in oncology utilizing the immune contexture of cancers. | $20.3M | Series B | Jan 17, 2018 |  |
| Sequana Medical | Sequana Medical is a Swiss medical device company providing implantable pump systems to manage fluid balance within the body. This system is designed to move excess fluid to the bladder, where it is passed naturally from the body through normal urination.Sequana Medical’s first product, the Alfapump System, is an innovative solution for themanagement of ascites. Ascites is a fluid that collects in the abdominal cavity in people with advanced liver disease, certain cancers, or congestive heart failure. Alfapump System was the first and only system for the automatic and continual removal of ascites.Sequana Medical was founded in 2006 and is based in Zurich, Switzerland. | $10.5M | Series C | Oct 23, 2015 |  |
| Kiadis Pharma | Kiadis Pharma is a biopharmaceutical company focused on complications and limitations of hematopoietic stem cell transplants in blood cancer patients. The company has three blood cancer products in clinical development that offer novel treatment options for terminally ill cancer patients addressing high-unmet medical needs. Kiadis Pharma isheadquartered in Amsterdam, The Netherlands. | $10.6M |  | Nov 20, 2012 |  |

10 of 24 investments shown.

## Co-investors
- [Capricorn Partners](https://shizune.co/investors/profile/capricorn-partners) — VC Fund, 13 deals together
- [Gimv](https://shizune.co/investors/profile/gimv) — VC Fund, 3 deals together
- [EQT Life Sciences](https://shizune.co/investors/profile/life-sciences-partners) — VC Fund, 3 deals together
- [SFPI-FPIM](https://shizune.co/investors/profile/sfpi-fpim) — VC Fund, 3 deals together
- [b2venture](https://shizune.co/investors/profile/btovpartners) — VC Fund, 2 deals together
- [Merifin Capital](https://shizune.co/investors/profile/merifin-capital) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [AME Cloud Ventures](https://shizune.co/investors/profile/ame-cloud-ventures) — VC Fund
- [Accel](https://shizune.co/investors/profile/accel) — VC Fund

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

### Similar country
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund
- [Limburgse Reconversie Maatschappij](https://shizune.co/investors/profile/limburgse-reconversie-maatschappij) — VC Fund
- [Qbic Fund](https://shizune.co/investors/profile/qbic-fund) — VC Fund

## Featured in investor lists
- [Biotechnology VC Funds in Belgium](https://shizune.co/investors/biotechnology-vc-funds-belgium)
- [Health Care VC Funds in Belgium](https://shizune.co/investors/health-care-vc-funds-belgium)
- [Biotech Investors in Belgium](https://shizune.co/investors/biotech-investors-belgium)
- [Biotech VC Funds in Belgium](https://shizune.co/investors/biotech-vc-funds-belgium)
- [Hardware Investors in Belgium](https://shizune.co/investors/hardware-investors-belgium)
- [Hardware VC Funds in Belgium](https://shizune.co/investors/hardware-vc-funds-belgium)

## FAQ

### What does Quest for Growth invest in?

Quest for Growth invests primarily in Biotechnology, Hardware and Software startups, most often at Funding Round and Series B stage. Most of the 24 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Quest for Growth's check size?

Quest for Growth typically joins rounds of $510k–$65M at Series B and $8.1M–$21M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Quest for Growth participates in.

### When did Quest for Growth last invest?

The most recent investment recorded for Quest for Growth closed in Jul 2024. Shizune tracks 24 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co